Oral anticoagulants (OACs) are medications commonly used in patients with atrial fibrillation and other cardiovascular conditions. Both warfarin and direct oral anticoagulants are susceptible to ...

Comprehensive characterization of therapeutic monoclonal antibody (mAb) structures is critical for drug development but remains challenging due to the inherent structural heterogeneity. In this study, ...

The maker of breast cancer drug Herceptin has applied for a licence for it to be used to treat the early stages of the disease. Manufacturer Roche claims its research shows the drug halves the risk of ...

Herceptin SC contains the active ingredient trastuzumab. Herceptin SC belongs to a group of medicines known as anti-neoplastic (or anti-cancer) agents. There are many different classes of anti ...

The NHS's drugs watchdog says people with early stage breast cancer should be able to get the drug Herceptin. The draft guidance from the National Institute for Health and Clinical Excellence (NICE) ...

ICH Q6B provides expectations and a clear framework for the structural characterization of biopharmaceutical products.

The inquests of Judith Ingham, 60, and Pearl Tatlow, 75, were opened by the coroner on Tuesday A further two inquests have been opened into the deaths of former patients of jailed surgeon Ian ...

For more than a decade, the first-line standard of care for locally advanced or metastatic HER2-positive breast cancer has been a taxane given with trastuzumab (Herceptin; Genentech) and ...

Data showed a median PFS of 40.7 months with Enhertu plus Perjeta versus 26.9 months with a taxane plus trastuzumab (Herceptin) and Perjeta. In the Enhertu and THP arms, respectively, the PFS rates ...

In the trial, treatment with Enhertu and Perjeta delayed cancer growth for longer than the established regimen of Perjeta, Herceptin and chemotherapy, which is known by the acronym THP.

The current first-line treatment for people with locally advanced or metastatic HER2-positive breast cancer is a taxane given in combination with the HER2-targeted therapy drugs trastuzumab ...

Results from the phase 2 segment of a phase 2/3 trial (NCT05980481) evaluating the antibody-drug conjugate disitamab vedotin (DV; Aidixi), PD-1 inhibitor toripalimab (Loqtorzi), and trastuzumab ...